文献速递特殊人群用药治疗药物监测与药物基因组学

妊娠期与哺乳期镰状细胞贫血的羟基脲治疗:当前证据与知识空白

Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps.
PubMed 文献 · Pharmacotherapy · 2023-03-26

综述妊娠期与哺乳期镰状细胞贫血(SCA)患者使用羟基脲的现有证据与知识空白。羟基脲在非妊娠成人和儿童中安全性良好,但因动物模型数据及超生理剂量的理论担忧,目前禁用于妊娠和哺乳期SCA女性;临床经验报告胎儿或婴儿不良结局不一致,暴露水平与妊娠结局的关系尚不明确,需系统评估暴露与安全性,并探索PBPK建模联合胎盘灌注测定等新方法。

要点

  • 羟基脲目前禁用于妊娠和哺乳期SCA女性,基于动物模型和超生理剂量的理论担忧。
  • 妊娠期使用羟基脲的临床报告胎儿或婴儿不良结局不一致,暴露水平与结局关系不明。
  • PBPK建模联合人胎盘小叶灌注测定有望明确妊娠和哺乳期安全有效的羟基脲剂量方案。

核心结论

  • 羟基脲在妊娠和哺乳期SCA女性中目前禁用,但临床经验报告的不良结局不一致,暴露与妊娠结局的关系尚不明确。
  • 需系统评估妊娠和哺乳期羟基脲治疗的暴露与安全性,以在治疗获益可能大于未治疗风险时确定安全有效剂量方案。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 羟基脲在非妊娠成人和儿童中安全性良好,但基于动物模型数据和超生理剂量理论担忧,目前禁用于妊娠和哺乳期SCA女性。
  • 妊娠期使用羟基脲的临床经验报告逐渐增多,但胎儿或婴儿不良结局结果不一致。
  • 羟基脲暴露水平与妊娠结局的相关性仍不明确。

关键数值与推荐

  • 羟基脲目前禁用于妊娠和哺乳期SCA女性。
  • 羟基脲在非妊娠成人和儿童中安全性良好。

临床怎么用

  • 妊娠和哺乳期SCA女性目前应避免使用羟基脲,除非在研究背景下或获益明确大于风险时个体化评估。
  • 需系统评估羟基脲在妊娠和哺乳期的暴露与安全性,以指导剂量方案制定。

局限性

  • 妊娠期羟基脲使用的临床经验报告结果不一致,暴露水平与妊娠结局关系不明确。
  • 现有安全性担忧主要基于动物模型数据和超生理剂量,缺乏妊娠和哺乳期人体系统暴露与安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell anemia (SCA) is a life-threatening genetic condition contributing to high-risk pregnancies affecting both the mother and fetus. With improved management of children with SCA, this life-threatening hematological disorder has evolved into a chronic disease of adults, and consequently parenthood has now become a possible and important life goal for many patients. Providing continuous management with healthy red blood cell function and avoiding SCA-associated complications, such as pain crises, acute chest syndrome, and stroke, are crucial for a healthy pregnancy. Despite its excellent safety profile in non-pregnant adults and children, and based on theoretical concerns derived from data using animal models and supraphysiological dosing, hydroxyurea is currently contraindicated for pregnant and lactating women with SCA. Clinical experience of hydroxyurea use during pregnancy is increasingly reported, however, and has shown inconsistent results of fetal or infant adverse effects. How the hydroxyurea exposure level may correlate with pregnancy outcomes is still unclear. Accordingly, efforts should be made to systemically evaluate exposure and safety of hydroxyurea treatment during pregnancy and lactation. Novel approaches such as physiologically based pharmacokinetic (PBPK) modeling, coupled with the ex vivo human placental cotyledon perfusion assay, provide opportunities to understand hydroxyurea exposure not only in pregnant women but also in the developing fetus. Combined with animal data, research using these approaches might be able to define safe and effective hydroxyurea dosing regimens for pregnant and lactating women with SCA, when the benefits of continuing hydroxyurea treatment likely outweigh the risks of non-treatment, by avoiding substantial morbidity and even mortality for both mothers and infants.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Dong M, Ware RE, Dallmann A, et al. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy. 2023. PMID: 36928875. doi:10.1002/phar.2793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。